CCME Global

{
  "main_header": {
    "sid": 187665,
    "name": "CCME Global",
    "stock_name": "CCME Global",
    "full_name": "CCME Global Ltd",
    "name_url": "stocks-analysis/ccme-global",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "103.74",
    "chg": 4.94,
    "chgp": "5.0%",
    "dir": 1,
    "prev_price": "98.80",
    "mcapval": "447.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 514336,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 40,
    "indexname": "India SENSEX",
    "isin": "INE194N01016",
    "curr_date": "Apr 24",
    "curr_time": "",
    "bse_nse_vol": "5.39 k",
    "exc_status": "Active",
    "traded_date": "Apr 24, 2026",
    "traded_date_str": "2026 04 24",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ccme-global-187665-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Genesis IBRC India Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/genesis-ibrc-india-ltd-is-rated-sell-3950691",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/GenesisIBRCIndi_mojoScore_3950691.png",
        "date": "2026-04-17 10:10:40",
        "description": "Genesis IBRC India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 January 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 17 April 2026, providing investors with an up-to-date analysis of the company’s standing."
      },
      {
        "title": "Genesis IBRC India Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/genesis-ibrc-india-ltd-is-rated-sell-3934298",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/GenesisIBRCIndi_mojoScore_3934298.png",
        "date": "2026-04-06 10:10:03",
        "description": "Genesis IBRC India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 April 2026, providing investors with an up-to-date perspective on the company’s performance and outlook."
      },
      {
        "title": "Genesis IBRC India Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/genesis-ibrc-india-ltd-is-rated-sell-3917965",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/GenesisIBRCIndi_mojoScore_3917965.png",
        "date": "2026-03-26 10:10:02",
        "description": "Genesis IBRC India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 March 2026, providing investors with the most up-to-date view of the company's performance and outlook."
      },
      {
        "title": "Genesis IBRC India Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/genesis-ibrc-india-ltd-is-rated-sell-3888392",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/GenesisIBRCIndi_mojoScore_3888392.png",
        "date": "2026-03-13 10:10:29",
        "description": "Genesis IBRC India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 Jan 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 13 March 2026, providing investors with an up-to-date analysis of the company’s standing."
      },
      {
        "title": "Genesis IBRC India Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/genesis-ibrc-india-ltd-is-rated-sell-3864120",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/GenesisIBRCIndi_mojoScore_3864120.png",
        "date": "2026-03-02 10:10:36",
        "description": "Genesis IBRC India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 March 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Genesis IBRC India Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/genesis-ibrc-india-ltd-is-rated-sell-3846717",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/GenesisIBRCIndi_mojoScore_3846717.png",
        "date": "2026-02-19 10:10:50",
        "description": "Genesis IBRC India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "When is the next results date for Genesis IBRC India Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-genesis-ibrc-india-ltd-3836101",
        "imagepath": "",
        "date": "2026-02-12 23:16:43",
        "description": "The next results date for Genesis IBRC India Ltd is scheduled for 14 February 2026...."
      },
      {
        "title": "Genesis IBRC India Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/genesis-ibrc-india-ltd-is-rated-sell-3827199",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/GenesisIBRCIndi_mojoScore_3827199.png",
        "date": "2026-02-08 10:10:29",
        "description": "Genesis IBRC India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 January 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 08 February 2026, providing investors with the latest comprehensive analysis."
      },
      {
        "title": "Genesis IBRC India Ltd Upgraded to Sell by MarketsMOJO Amid Flat Financials and Valuation Concerns",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/genesis-ibrc-india-ltd-upgraded-to-sell-by-marketsmojo-amid-flat-financials-and-valuation-concerns-3806769",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/GenesisIBRCIndi_mojoScore_3806769.png",
        "date": "2026-01-28 08:05:02",
        "description": "Genesis IBRC India Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 27 Jan 2026, reflecting a nuanced shift in its financial and market outlook. Despite persistent challenges in profitability and valuation, certain technical and financial trend parameters have shown stabilisation, prompting a reassessment of the company’s investment appeal within the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 183,
    "sid": "187665",
    "stock_news_url": "https://www.marketsmojo.com/news/ccme-global-187665"
  },
  "announcements": [
    {
      "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A",
      "datetime": "17-Apr-2026",
      "details": "<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Genesis Ibrc India Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24100AP1992PLC107068</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>0</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Garima Garg <br/> Designation: Company Secretary And Compliance Officer <br/> EmailId: csgenesisiil@gmail.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Ravindranath Rajaram <br/> Designation: Chief Financial Officer <br/> EmailId: r.ravindranath87@gmail.com</div> </div> <div> <br/> Date: 17/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting For Appointment Of Company Secretary Compliance Officer And KMP. Also For Situation Of Corporate Office And Keeping Books Of Accounts At The Place Other Than Registered Office.",
      "datetime": "08-Apr-2026",
      "details": "Outcome of board meeting for appointment of Company Secretary Compliance Officer and KMP. Also for situation of corporate office and keeping books of accounts at the place other than the Companys registered office.",
      "source": "BSE"
    },
    {
      "caption": "Appointment of Company Secretary and Compliance Officer",
      "datetime": "08-Apr-2026",
      "details": "Appointment of Company Secretary Compliance Officer and KMP.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Genesis IBRC India Ltd is Rated Sell

2026-04-17 10:10:40

Genesis IBRC India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 January 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 17 April 2026, providing investors with an up-to-date analysis of the company’s standing.

Read full news article

Genesis IBRC India Ltd is Rated Sell

2026-04-06 10:10:03

Genesis IBRC India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 April 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Read full news article

Genesis IBRC India Ltd is Rated Sell

2026-03-26 10:10:02

Genesis IBRC India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 March 2026, providing investors with the most up-to-date view of the company's performance and outlook.

Read full news article

Genesis IBRC India Ltd is Rated Sell

2026-03-13 10:10:29

Genesis IBRC India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 Jan 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 13 March 2026, providing investors with an up-to-date analysis of the company’s standing.

Read full news article

Genesis IBRC India Ltd is Rated Sell

2026-03-02 10:10:36

Genesis IBRC India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 March 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Genesis IBRC India Ltd is Rated Sell

2026-02-19 10:10:50

Genesis IBRC India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

When is the next results date for Genesis IBRC India Ltd?

2026-02-12 23:16:43

The next results date for Genesis IBRC India Ltd is scheduled for 14 February 2026....

Read full news article

Genesis IBRC India Ltd is Rated Sell

2026-02-08 10:10:29

Genesis IBRC India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 January 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 08 February 2026, providing investors with the latest comprehensive analysis.

Read full news article

Genesis IBRC India Ltd Upgraded to Sell by MarketsMOJO Amid Flat Financials and Valuation Concerns

2026-01-28 08:05:02

Genesis IBRC India Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 27 Jan 2026, reflecting a nuanced shift in its financial and market outlook. Despite persistent challenges in profitability and valuation, certain technical and financial trend parameters have shown stabilisation, prompting a reassessment of the company’s investment appeal within the Pharmaceuticals & Biotechnology sector.

Read full news article

View All News